Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 494 entries
View as:

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

Phase: N/A Priority: Normal
NCT ID: NCT00527410 Org: User:
Start: 10/31/06 End: - Due: -

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

Phase: N/A Priority: Normal
NCT ID: NCT06555419 Org: User:
Start: 01/16/25 End: 05/15/26 Due: 05/15/27

Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Phase: N/A Priority: Normal
NCT ID: NCT02865109 Org: User:
Start: - End: - Due: -

Angelman Syndrome (AS) Biomarker Study

Phase: N/A Priority: Normal
NCT ID: NCT04103333 Org: User:
Start: 12/18/19 End: 01/02/22 Due: 01/02/23

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01511510 Org: User:
Start: 06/30/11 End: 11/30/11 Due: 11/30/12

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

Phase: N/A Priority: Normal
NCT ID: NCT00915577 Org: User:
Start: 08/31/05 End: 04/30/06 Due: 04/30/07

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Phase: N/A Priority: Normal
NCT ID: NCT06935357 Org: User:
Start: 05/08/25 End: 06/05/29 Due: 06/05/30

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01281111 Org: User:
Start: 02/01/11 End: 03/18/11 Due: 03/18/12

A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)

Phase: N/A Priority: Normal
NCT ID: NCT05895552 Org: User:
Start: 07/28/23 End: 11/15/24 Due: 11/15/25

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00048555 Org: User:
Start: 11/30/02 End: 11/30/10 Due: 11/30/11

A Real-world Study of Imraldi® Use

Phase: N/A Priority: Normal
NCT ID: NCT04089514 Org: User:
Start: 06/30/19 End: 11/30/21 Due: 11/30/22

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

Phase: N/A Priority: Normal
NCT ID: NCT02292537 Org: User:
Start: 11/24/14 End: 02/20/17 Due: 02/20/18

Pregnancy Exposure Registry for Tysabri®

Phase: N/A Priority: Normal
NCT ID: NCT00472992 Org: User:
Start: 01/31/07 End: 07/31/12 Due: 07/31/13

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

Phase: N/A Priority: Normal
NCT ID: NCT01652937 Org: User:
Start: 08/31/12 End: 03/31/14 Due: 03/31/15

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT03926637 Org: User:
Start: 06/17/19 End: 12/05/22 Due: 12/05/23

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02484547 Org: User:
Start: 09/15/15 End: 08/05/19 Due: 08/05/20

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Phase: N/A Priority: Normal
NCT ID: NCT02978326 Org: User:
Start: 01/04/17 End: 12/11/18 Due: 12/11/19

A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

Phase: N/A Priority: Normal
NCT ID: NCT06685757 Org: User:
Start: 12/03/24 End: 06/01/27 Due: 06/01/28

Natural Disease Progression in Participants With Choroideremia

Phase: N/A Priority: Normal
NCT ID: NCT04795206 Org: User:
Start: 08/26/20 End: 08/10/21 Due: 08/10/22

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06454721 Org: User:
Start: 01/30/25 End: 07/30/26 Due: 07/30/27

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04494256 Org: User:
Start: 09/28/20 End: 08/13/24 Due: 08/13/25

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Phase: N/A Priority: Normal
NCT ID: NCT05701423 Org: User:
Start: 02/08/23 End: 07/31/24 Due: 07/31/25

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

Phase: N/A Priority: Normal
NCT ID: NCT05531565 Org: User:
Start: 09/13/22 End: 12/14/27 Due: 12/14/28

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

Phase: N/A Priority: Normal
NCT ID: NCT02847598 Org: User:
Start: 10/20/16 End: 11/18/19 Due: 11/18/20

Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00531193 Org: User:
Start: 09/30/07 End: 04/30/08 Due: 04/30/09